RT Journal Article
T1 Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry.
A1 Nuñez-Gil, Ivan J
A1 Fernandez-Perez, Cristina
A1 Estrada, Vicente
A1 Becerra-Muñoz, Victor M
A1 El-Battrawy, Ibrahim
A1 Uribarri, Aitor
A1 Fernandez-Rozas, Inmaculada
A1 Feltes, Gisela
A1 Viana-Llamas, Maria C
A1 Trabattoni, Daniela
A1 Lopez-Pais, Javier
A1 Pepe, Martino
A1 Romero, Rodolfo
A1 Castro-Mejia, Alex F
A1 Cerrato, Enrico
A1 Astrua, Thamar Capel
A1 D'Ascenzo, Fabrizio
A1 Fabregat-Andres, Oscar
A1 Moreu, Jose
A1 Guerra, Federico
A1 Signes-Costa, Jaime
A1 Marin, Francisco
A1 Buosenso, Danilo
A1 Bardaji, Alfredo
A1 Raposeiras-Roubin, Sergio
A1 Elola, Javier
A1 Molino, Angel
A1 Gomez-Doblas, Juan J
A1 Abumayyaleh, Mohammad
A1 Aparisi, Alvaro
A1 Molina, Maria
A1 Guerri, Asuncion
A1 Arroyo-Espliguero, Ramon
A1 Assanelli, Emilio
A1 Mapelli, Massimo
A1 Garcia-Acuña, Jose M
A1 Brindicci, Gaetano
A1 Manzone, Edoardo
A1 Ortega-Armas, Maria E
A1 Bianco, Matteo
A1 Trung, Chinh Pham
A1 Nuñez, Maria Jose
A1 Castellanos-Lluch, Carmen
A1 Garcia-Vazquez, Elisa
A1 Cabello-Clotet, Noemi
A1 Jamhour-Chelh, Karim
A1 Tellez, Maria J
A1 Fernandez-Ortiz, Antonio
A1 Macaya, Carlos
K1 COVID-19
K1 Mortality
K1 Prognosis
K1 Registry
K1 Score
AB Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation  0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399.
PB Springer
YR 2020
FD 2020-10-15
LK http://hdl.handle.net/10668/16570
UL http://hdl.handle.net/10668/16570
LA en
NO Núñez-Gil IJ, Fernández-Pérez C, Estrada V, Becerra-Muñoz VM, El-Battrawy I, Uribarri A, et al. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. Intern Emerg Med. 2021 Jun;16(4):957-966
DS RISalud
RD Apr 7, 2025